Subgroup analysis results of overall survival in advanced NSCLC patients according to <i>BRCA1</i> rs1799966 genotypes (TT <i>vs.</i> TC+CC).

<p>(A) Squamous cell carcinoma group, (B) ever smokers group, (C) ECOG performance status  = 1 group, (D) stage III group. Number in parenthesis, number of deaths/number of cases.</p

Associations of Polymorphisms in DNA Repair Genes and MDR1 Gene with Chemotherapy Response and Survival of Non-Small Cell Lung Cancer

<div><p>Objectives</p><p>We aimed to determine the associations of genetic polymorphisms of excision repair cross-complementation group 1 (<i>ERCC1</i>) rs11615, xeroderma pigmentosum group D (<i>XPD</i>/<i>ERCC2)</i> rs13181, X-ray repair cross complementing group 1 (<i>XRCC1</i>) rs25487, <i>XRCC3</i> rs1799794, and breast cancer susceptibility gene 1 (<i>BRCA1</i>) rs1799966 from the DNA repair pathway and multiple drug resistance 1 (<i>MDR1/ABCB1</i>) rs1045642 with response to chemotherapy and survival of non-small cell lung cancer (NSCLC) in a Chinese population.</p><p>Materials and Methods</p><p>A total of 352 NSCLC patients were enrolled to evaluate the associations of the six SNPs with response to chemotherapy and overall survival. Logistic regressions were applied to test the associations of genetic polymorphisms with response to chemotherapy in 161 advanced NSCLC patients. Overall survival was analyzed in 161 advanced and 156 early stage NSCLC patients using the Kaplan-Meier method with log-rank test, respectively. Multivariate Cox proportional hazards model was performed to determine the factors independently associated with NSCLC prognosis.</p><p>Results</p><p><i>BRCA1</i> rs1799966 minor allele C (TC+CC <i>vs.</i> TT, OR = 0.402, 95%CI = 0.204−0.794, p = 0.008) and <i>MDR1/ABCB1</i> rs1045642 minor allele A (GA +AA <i>vs.</i> GG, OR = 0.478, 95%CI = 0.244−0.934, p = 0.030) were associated with a better response to chemotherapy in advanced NSCLC patients. Survival analyses indicated that <i>BRCA1</i> rs1799966 TC+CC genotypes were associated with a decreased risk of death (HR = 0.617, 95% CI = 0.402−0.948, p = 0.028) in advanced NSCLC patients, and the association was still significant after the adjustment for covariates. Multivariate Cox regression analysis showed that <i>ERCC1</i> rs11615 AA genotype (<i>P</i> = 0.020) and smoking (p = 0.037) were associated with increased risks of death in early stage NSCLC patients after surgery.</p><p>Conclusions</p><p>Polymorphisms of genes in DNA repair pathway and <i>MDR1</i> could contribute to chemotherapy response and survival of patients with NSCLC.</p></div

Subgroup analysis results of overall survival in early stage NSCLC patients according to <i>ERCC1</i> genotypes (GG+GA vs. AA).

<p>(A) Squamous cell carcinoma group, (B) ever smokers group, (C) ECOG performance status  = 1 group, (D) never receiving radiation therapy group. Number in parenthesis, number of deaths/number of cases.</p

Demographic and clinical characteristics of the NSCLC patients.

<p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, stand deviation.</p><p>*<i>P</i> values refer to the comparison between early stage patients with surgery and advanced patients with chemotherapy. Student's t-test was used to compare age as a continuous variable; chi-square test was used to compare categorical variables, except for ECOG performance status, where Fisher's exact test was used.</p>†<p>Comparisons between never smokers and ever smokers.</p

Factors associated with overall survival of early stage NSCLC patients.

<p>(A) <i>ERCC1</i> rs11615, (B) smoking status.</p

Factors associated with overall survival of advanced NSCLC patients.

<p>(A) <i>BRCA1</i> rs1799966, (B) radiation therapy, (C) smoking status.</p

Associations of genotype and clinical stage with clinical benefit of chemotherapy among advanced NSCLC patients (N = 161).

<p>Abbreviations: CR, complete response; OR, odds ratio; PD, progressive disease; PR, partial response; SD, stable disease.</p><p>*Adjusted for <i>BRCA1</i> rs1799966, <i>MDR1/ABCB1</i> rs1045642 and clinical stage, adjusted ORs and P values were obtained from multivariate logistic regression analysis by forward stepwise method.</p

Supplementary Data from Development of Autoantibody Signatures as Novel Diagnostic Biomarkers of Non–Small Cell Lung Cancer

Supplementary Tables S1-S7.</p

Additional file 1 of The bisphenol F and bisphenol S and cardiovascular disease: results from NHANES 2013–2016

Additional file 1: Fig S1. The restricted cubic spline model was used to analyze the relationship between Bisphenols and the risk of CVD. A BPS; B BPF; C BPA. The analysis adjusted for gender, age, race, education level, PIR, physical activity, alcohol drinking status, smoking status, BMI, blood pressure, cancer, diabetes, LDL-C, energy, urine creatinine

Number (%) of community residents correctly answering the 11 questions in knowledge test section.

<p>Number (%) of community residents correctly answering the 11 questions in knowledge test section.</p